Naproxcinod
Clinical data | |
---|---|
Other names | AZD-3582, HCT-3012 |
ATC code | |
Identifiers | |
| |
JSmol) | |
| |
| |
(what is this?) (verify) |
Naproxcinod (nitronaproxen) is a
In December 2006,
Current situation in pain treatment
Many people are currently relying on traditional NSAIDs and
Indications
Three phase III clinical trials led by NicOx have shown that naproxcinod was effective to treat pain against knee osteoarthritis[6][7][8] and hip osteoarthritis.[9] A phase II study showed no significant differences in efficacy between naproxcinod and the COX-2 inhibitor rofecoxib in the treatment of pain.[10]
In osteoarthritis, a 750 mg dose is equipotent to 500 mg of naproxen for the treatment of inflammation but with the added benefit of attenuating the cardiovascular effects traditionally associated with NSAIDs.[11]
In July 2010 the FDA decided not to approve naproxcinod.[4]
Mechanism of action
Naproxcinoid is metabolized to naproxen and a nitric oxide donating
Safety profile
Blood pressure profile
According to some experts[
Clinical relevance of small increase in blood pressure
During a
A 2005 analysis shows that a blood pressure decrease of 3.1 mmHG could avoid over 30,000 deaths from stroke and 2,000 deaths from
Gastrointestinal safety
NSAIDs have also been associated with
Contraindications and adverse effects
This section needs expansion. You can help by adding to it. (October 2009) |
Similarly to NSAIDs, adverse effects of naproxcinod include gastrointestinal bleedings.[19][20]
Commercialization
Naproxcinod completed a phase III study needed for a New Drug Application (NDA). As a result, Nicox submitted its project to the FDA in September 2009.[21] In July 2010, the FDA decided not to approve naproxcinod without further clinical trials.[4] Nicox submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMEA) in December 2009.[22] Nicox and Fera Pharmaceuticals announced in November 2015 that they had entered into a license agreement for the development and commercialization of naproxcinod in the United States.[23]
See also
- Nitrosoprodenafil – a dual PDE5 inhibitor / NO donor
References
- S2CID 3231846.
- PMID 16613570.
- ^ Special Report: 10 Promising Treatments for World's Biggest Health Threats, By Charles Q. Choi. 2006
- ^ a b c NicOx Shares Plummet as FDA Says Osteoarthritis Drug Not Ready for Approval
- S2CID 39981292.
- ^ "NicOx Announces Top-Line Results From Naproxcinod 52-Week 301 Safety Extension". 24 July 2008. Retrieved 2 February 2010.
- ^ Clinical trial number NCT00542555 for "Analgesic Efficacy and Safety Study of Naproxcinod in Subjects With Osteoarthritis of the Knee" at ClinicalTrials.gov
- ^ Clinical trial number NCT00504127 for "Efficacy and Safety Study of Naproxcinod in Subjects With Osteoarthritis of the Knee" at ClinicalTrials.gov
- ^ Clinical trial number NCT00541489 for "Efficacy and Safety Study of Naproxcinod in Subjects With Osteoarthritis of the Hip" at ClinicalTrials.gov
- ^ PMID 19411388.
- ^ PMID 19733721.
- PMID 19230986.
- ^ "Analysis of FDA COX-2 Advisory Committee Meeting" (PDF). 2005. p. 21.
- PMID 15536108.
- PMID 12683425.
- S2CID 19825259.
- S2CID 8025524.
- PMID 14570719.
- ^ S2CID 70711735.
- ^ a b Schubert-Zsilavecz, M, Wurglics, M, Neue Arzneimittel 2010
- ^ Michelson M (25 September 2009). "NicOx submits naproxcinod application to FDA". Reuters. Retrieved 3 February 2010.
- ^ "MAA for naproxcinod submitted to EMEA through centralized procedure". NewsMedical.net. 22 December 2009. Retrieved 2 February 2010. [dead link]
- ^ "Fera Pharmaceuticals - Press Releases". www.ferapharma.com. Retrieved 20 April 2016.